Clinical Trial

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Study acronym: INTRIGUE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
Protocol Amendment History 30 amendments
This ClinicalTrials.gov record has been amended 30 times since 2018-09-14; most recent amendment 2026-01-16.
Status change: Recruiting → Active, Not Recruiting 2021-01-04
Status change: Not Yet Recruiting → Recruiting 2018-12-20
Trial Details
NCT Number NCT03673501
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Gastrointestinal Stromal Tumors
Enrollment 453 participants
Start Date 2019-02-08
Primary Completion 2021-09-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-05